Formulary Allocations - 1 November 2024
Page last updated: 1 November 2024
The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument. Single brand combination drugs are not included in either the F1 or F2 formulary.
Drugs with "Combination Drugs List" in the second column are those drugs which, in accordance with ss85AB(5) are not allocated to any formulary.
Note:
- From 1 March 2024 the Formulary Allocations will be provided as an Excel file.
- New drugs with Formulary Allocations or changes for this month are highlighted.
- Some drug names have changed as a result of the Therapeutic Goods Administration’s International Harmonisation of Ingredient Names reform to bring medicine ingredient names in line with international nomenclature. These changes will have no material impact on the formulary allocation of drugs on the Pharmaceutical Benefits Scheme. For easy reference, medicines with name changes are indicated with a number in the Legislative Instrument Drug Name column in the table, with the corresponding endnote describing the change to that medicine.
